Market revenue in 2023 | USD 982.9 million |
Market revenue in 2030 | USD 2,704.2 million |
Growth rate | 15.6% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Infectious Diseases |
Historical data covered | 2021 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Infectious Diseases |
Key market players worldwide | Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Latin America mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
The mRNA therapeutics market in Latin America is gaining momentum, driven by increasing healthcare infrastructure and growing awareness of advanced medical treatments. Drivers include a surge in government initiatives, like Brazil’s commitment to vaccine development, fostering collaboration with mRNA technology developers.
Notably, partnerships between local pharmaceutical companies and global leaders, similar to the collaboration between Argentina’s Laboratories Richmond and Russia’s Gabaliya Research Institute for Sputnik V production, showcase the region’s potential.
In addition, In February 2022, Moderna, Inc. took a significant step in the Latin American market by entering a distribution service agreement with Adium Pharma S.A. The partnership aimed to facilitate the commercialization of the Moderna COVID-19 vaccine, Spikevax, across 18 countries in Latin America, including major nations like Brazil, Mexico, Colombia, and Argentina.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America mrna therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America mrna therapeutics market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account